REFERENCES
1. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Myerson M, Gabriel SB, Lander ES, Getz G. Discovery and saturation analysis of cancer genes across 21 tumor types. Nature 2014;505:495-501.
2. Martincorena I, Roshan A, Gerstung M, Van Loo P, McLaren S, Wedge DC, Fullam A, Alexandrov LB, Tubio JM, Stebbings L, Menzies A, Widaa S, Stratton MR, Jones PH, Campbell PJ. Tumor evolution. High burden and pervasive selection of somatic mutations in normal human skin. Science 2015;348:880-6.
3. Schaefer MH, Serrano L. Cell type-specific properties and environment shape tissue specificity of cancer genes. Sci Rep 2016;6:2707.
4. Williamson LM, Lees-Miller SP. Estrogen receptor a-mediated transcription induces cell cycle-dependent DNA double-strand breaks. Carcinogenesis 2011;32:279-85.
5. Savage KI, Matchett KB, Barros EM, Cooper KM, Irwin GW, Gorski JJ, Orr KS, Vohhodina J, Kavanagh JN, Madden AF, Powell A, Manti L, McDade SS, Park BH, Prise KM, McIntosh SA, Salto-Tellez M, Richard DJ, Elliott CT, Harkinet DP. BRCA1 deficiency exacerbates estrogen-induced DNA damage and genomic instability. Cancer Res 2014;74:2773-84.
6. Kleppe M, Levine RL. Tumor heterogeneity confounds and illuminates: assessing the implications. Nat Med 2014;20:342-4.
7. Gottlieb B, Alvarado C, Wang C, Gharizadeh B, Babrzadeh F, Richards B, Basik M, Beitel LK, Trifiro M. Making sense of intra-tumor genetic heterogeneity: altered frequency of androgen receptor CAG repeat length variants in breast cancer tissues. Hum Mutat 2013;34:610-8.
8. Ng CK, Scultheis AM, Bidard FC, Wegelt B, Reis-Filho JS. Breast cancer genomics from microarray to massively parallel sequencing: paradigms and new insights. J Natl Cancer Inst 2015;107:djv015.
9. Wang Y, Waters J, Leung ML, Unruh Roh W A, Shi X, Chen K, Scheet Vattathil S P, Liang H, Multani A, Zhang H, Zhao R, Michor F, Meric-Bernstam F, Navin NE. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 2014;512:155-60.
10. Raphael BJ, Dobson JR, Oesper L, Vandin F. Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. Genome Med 2014;6:5.
11. McFarland CA, Yaglom YA, Wojtkowiak JW, Scott JG, Morse DL, Sherman MY, Mirny LA. The damaging effect of passenger mutations on cancer progression. Cancer Res 2017;77:4763-72.
12. Fortunato A, Boddy A, Mallo D, Aktipis A, Maley CC, Pepper JW. Natural selection in cancer biology: from molecular snowflakes to trait hallmarks. Cold Spring Harb Perspect Med 2017;7:a029652.
13. Schirmer M, Ijaz UZ, D'Amore R, Hall N, Sloan WT, Quince C. Insight into biases and sequencing errors for amplicon sequencing with the Illumina MiSeq platform. Nucleic Acids Res 2015;43:e37.
14. Forsberg LA, Gisselsson D, Damanski JP. Mosaicism in health and disease - clones picking up speed. Nat Rev Genet 2017;18:128-42.
15. Hoang ML, Kinde I, Tomasetti C, Wyatt McMahon K, Rosenquist TA, Grollman AP, Kinzler KW, Vogelstein B, Papadopoulos N. Genome-wide quantification of rare somatic mutations in normal human tissues using massively parallel sequencing. PNAS 2016;113:9846-51.
16. Anglesio MS, Papadopoulos N, Ayhan A, Nazeran TM, Noë M, Horlings HM, Lum A, Jones S, Senz J, Seckin T, Ho J, Wu RC, Lac V, Ogawa H, Tessier-Cloutier B, Alhassan R, Wang A, Wang Y, Cohen JD, Wong F, Hasanovic A, Orr N, Zhang M, Popoli M, McMahon W, Wood LD, Mattox A, Allaire C, Segars J, Williams C, Tomasetti C, Boyd N, Kinzler KW, Gilks CB, Diaz L, Wang TL, Vogelstein B, Yong PJ, Huntsman DG, Shih IM. Cancer-associated mutations in endometriosis without cancer. N Engl J Med 2017;376:1835-48.
17. Guedj M, Marisa I, de Renies A, Orsetti B, Schiappa R, Bibeau F, MacGrogan G, Lerebours F, Finetti P, Longy M, Bertheau P, Bertrand F, Bonnet F, Martin AL, Feugeas JP, Bièche I, Lehmann-Che J, Lidereau R, Birnbaum D, Bertucci F, de Thé H, Theillet C. A refined molecular taxonomy of breast cancer. Oncogene 2012;31:1196-206.
18. Lehnann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750-67.
19. Hirschfield KM, Ganesan S. Triple-negative breast cancer: molecular subtypes and targested therapy. Curr Opin Obstet Gyncol 2014;26:34-40.
20. Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, Tamimi RM. Androgen expression in breast cancer in relation to molecular phenotype: results from the Nurses Health Study. Mod Pathol 2011;24:924-31.
21. Fujii R, Hanamura T, Sizuki T, Gohno T, Shibahara Y, Niwa T, Yamaguchi Y, Ohnuki K, Kakugawa Y, Hirakawa H, Ishida T, Sasano H, Ohuchi N, Hayashi S. Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma. J Steroid Biochem Mol Biol 2014;144:513-22.
22. Peters KM, Edwards SL, Nair SS, French JD, Bailry PJ, Salkield K, Stein S, Wagner S, Francis GD, Clark SJ, Brown MA. Androgen receptor expression predicts cancer survival: the role of genetic and epigenetic events. BMC Cancer 2012;12:132.
23. MacNamara KM, Moore NL, Hickey TE, Sasano H, Tiley WD. Complexities of androgen receptor signaling in breast cancer. Endocr Relat Cancer 2014;21:T161-81.
24. Gottlieb B, Beitel LK, Nadarajah A, Paliouras M, Trifiro M. The androgen receptor gene mutations database (ARDB): 2012 update. Hum Mutat 2012;33:887-94.
25. Brockman W, Alvarez P, Young S, Garber M, Gainnoukos G, Lee WI, Russ C, Lander ES, Nusbaum C, Jaffe DB. Quality scores and SNP detection in sequencing-by-sequencing systems. Genome Res 2008;19:767-70.
26. Shao W, Boltz VF, Spindler JE, Kearney MF, Maldarelli F, Mellors JW, Stewart C, Volfovsky N, Levitsky A, Stephens RM, Coffin JM. Analysis of 454 sequencing error rate, error sources, and artifact recombination for detection of low-frequency drug resistance mutations in HIV-1 DNA. Retrovirology 2013;10:18.
27. Behjati S, Huch M, van Boxtel R, Karthaus W, Wedge DC, Tamuri AU, Martincorena I, Petljak M, Alexandrov LB, Gundem G, Patrick S, Tarpey PS, Roerink S, Blokker J, Maddison M, Mudie L, Robinson B, Nik-Zainal S, Campbell P, Goldman N, van de Wetering M, Cuppen E, Clevers H, Stratton MR. Genome sequencing of normal cells reveals developmental lineages and mutational processes. Nature 2014;513:422-5.
28. Gulukota K, Helseth DL Jr, Khadekar JD. Direct observation of genomic heterogeneity through local haplotyping analysis. BMC Genomics 2014;15:418.
29. Makohon-Moore AP, Zhang M, Reiter JG, Bozic I, Allen B, Kundu D, Chatterjee K, Wong F, Jiao Y, Kohutek ZA, Hong J, Attiyeh M, Javier B, Wood LD, Hruban RH, Nowak MA, Papadopoulos N, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA. Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nat Genet 2017;49:358-66.
30. Chen L, Liu P, Evans TC Jr, Ettwiller L. DNA damage is a major cause of sequencing errors, directly confounding variant identification. Science 2017;355:752-6.
31. Lander ES, Waterman MS. Genomic mapping by fingerprinting random clones: a mathematical analysis. Genomics 1988;2:231-9.
32. Sims D, Sudbery I, Ilott NE, Heger A, Ponting CP. Sequencing depth and coverage: key considerations in genomic analysis. Nat Rev Genet 2014;15:121-32.
33. Hatem A, Bozdag D, Toland AE, Catalyurek UV. Benchmarking short sequence mapping tools. BMC Bioinformatics 2013;14:184.
34. Flaherty P, Natsoulis G, Muralidharan O, Winters M, Buenrostro J, Bell J, Brown S, Holodniy M, Zhang N, Ji HP. Ultrasensitive detection of rare mutations using next-generation targeted sequencing. Nucleic Acids Res 2012;40:e2.
35. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES, Getz G. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotech 2013;31:213-9.
36. Ostrow SL, Barshir R, DeGregori J, Yeger-Lotem E, Hershberg R. Cancer evolution is associated with pervasive positive selection on globally expressed genes. PLoS Genet 2014;10:e1004239.
37. Thomas F, Ujvan B, Renaud F, Vincent M. Cancer adaptations: atavism, de novo selection, or something in between? Bioessays 2017;39:1700039.
38. Polyak K. Tumor heterogeneity confounds and illuminates: a case of Darwinian tumor evolution. Nature Med 2014;20:344-6.
40. Zhu T, j Ye, Han I, Qiu QW, Zhang H, Liang L, Gu X. Variations in genotype-phenotype correlations in phenylalanine hydroxylate deficiency in Chinese Han population. Gene 2013;529:80-7. in Chinese
41. Cooper DN, Krawczak M, Polychronakos C, Tyler-Smith C, Kehrer-Sawatzki H. Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease. Hum Genet 2013;132:1077-130.
42. Chen R, Shi L, Hakenberg J, Naughton B, Sklar P, Zhang J, Zhou H, Tian L, Prakash O, Lemire M, Sleiman P, Cheng WH, Chen W, Shah H, Shen Y, Fromer M, Omberg L, Deardorff MA, Zackai E, Bobe JR, Levin E, Hudson TJ, Groop L, Wang J, Hakonarson H, Wojcicki A, Diaz GA, Edelmann L, Schadt EE, Friend SH. Analysis of 589,306 genomes identifies individuals resilient to severe Mendelian childhood diseases. Nat Biotechnol 2016;34:531-8.
43. Youseef O, Knuuttila A, Piirla P, Bohling T, Sargadi V, Knuutila S. Presence of cancer-associated mutations in exhaled breath condensates of healthy individuals by next generation sequencing. Oncotarget 2017;8:18166-76.
44. Calado F, Siva-Santos B, Norell H. Intra-tumor heterogeneity going beyond genetics. FEBS J 2016;283:2245-58.
45. Gottlieb B, Beitel LK, Trifiro M. Changing genetic paradigms: creating next-generation genetic databases as tools to understand the emerging complexities of genotype/phenotype relationships. Hum Genomics 2014;8:9.
46. Gottlieb B, Beitel LK, Alvarado C, Trifiro MA. Selection and mutation in the "new" genetics: an emerging hypothesis. Hum Genet 2010;127:491-501.
47. Ju YS, Martincorena I, Gerstung M, Petljak M, Alexandrov LB, Rahbari R, Wedge DC, Davies HR, Ramakrishna M, Fullam A, Martin S, Alder C, Patel N, Gamble S, O'Meara S, Giri DD, Sauer T, Pinder SE, Purdie CA, Å Borg, Stunnenberg H, van de Vijver M, Tan BK, Caldas C, Tutt A, Ueno NT, van 't Veer LJ, Martens JW, Sotiriou C, Knappskog S, Span PN, Lakhani SR, Eyfjörd JE, Børresen-Dale AL, Richardson A, Thompson AM, Viari A, Hurles ME, Nik-Zainal S, Campbell PJ, Stratton MR. Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. Nature 2017;543:714-8.
48. Liggett LA, DeGregori J. Changing mutational and adaptive landscapes and the genesis of cancer. Biochem Biophys Acta 2017;1867:84-94.
49. Scott J, Marusyk A. Somatic clonal evolution: a selection-centric perspective. Biochem Biophys Acta 2017;1867:139-50.
50. Kerr J, Anderson C, Lippman SM. Physical activity, sedentary behavior, diet and cancer: an update and emerging new evidence. Lancet Oncol 2017;18:e457-71.
51. Hochberg ME, Noble RJ. A framework for how environment contributes to cancer risk. Ecology Letters 2017;20:117-34.
52. Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, Gong Z, Zhang S, Zhou J, Cao K, Li X, Xiong W, Li G, Zeng Z. Role of tumor microenvironment in tumorigenesis. J Cancer 2017;8:761-73.
53. Hirata E, Sahai E. Tumor microenvironment and differential responses to therapy. Cold Spring Harb Perspect Med 2017;7:a026781.
54. Jorba I, Uriarte JJ, Campillo N, Farre R, Navajas D. Probing micromechanical properties of the extracellular matrix of soft tissues by atomic force microscopy. J Cell Physiol 2017;232:19-26.
55. Goddard ET, Ryan C, Hill RC, Barrett A, Betts C, Guo Q, Maller O, Borges VF, Hansen KC, Schedin P. Quantitative extracellular matrix proteomics to study mammary and liver tissue microenvironments. Intl J Biochem Cell Biol 2016;81:223-32.
